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1It is well known that the presence of left ventricular (LV) hyper-trophy by echocardiography predicts increased cardiovascu-
lar morbidity and mortality both in general and in hypertensive 
populations.1–3 In patients with aortic valve stenosis (AS), LV 
hypertrophy is mainly considered an adaptive response that 
keeps LV wall stress close to normal, offsetting the hemody-
namic load.4 However, as recently demonstrated, the presence 
of concomitant hypertension, obesity, and metabolic syndrome 
significantly modulates LV mass and geometry in patients with 
asymptomatic AS independent of AS severity.5–7
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Few studies in AS have focused on the prognostic impact 
of LV mass. In patients with severe symptomatic AS, con-
centric LV geometry and severe LV hypertrophy by echocar-
diography have been associated with increased mortality after 
aortic valve replacement.8,9 Increased cardiovascular morbid-
ity and mortality has also been demonstrated for asymptom-
atic patients with severe AS and excessive LV hypertrophy.10 
Recently, higher LV mass was associated with worse outcome 
after transcatheter aortic valve replacement for severe symp-
tomatic AS.11 However, the independent prognostic impact 
of LV mass by echocardiography in asymptomatic mild-
to-moderate AS patients has not been reported from a large 
prospective study. Thus, the aim of this study was to test the 
Background—The prognostic importance of left ventricular (LV) mass in nonsevere asymptomatic aortic stenosis has not 
been documented in a large prospective study.
Methods and Results—Cox regression analysis was used to assess the impact of echocardiographic LV mass on rate of 
major cardiovascular events in 1656 patients (mean age, 67 years; 39.6% women) with mild-to-moderate asymptomatic 
aortic stenosis participating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study. Patients were followed 
during 4.3 years of randomized treatment with combined simvastatin 40 mg and ezetimibe 10 mg daily or placebo. 
At baseline, LV mass index was 45.9+14.9 g/m2.7, and peak aortic jet velocity was 3.09+0.54 m/s. During follow-up, 
558 major cardiovascular events occurred. In Cox regression analyses, 1 SD (15 g/m2.7) higher baseline LV mass index 
predicted increases in hazards of 12% for major cardiovascular events, 28% for ischemic cardiovascular events, 34% 
for cardiovascular mortality, and 23% for combined total mortality and hospitalization for heart failure (all P<0.01), 
independent of confounders. In time-varying models, taking the progressive increase in LV mass index during follow-
up into account, 1 SD higher in-study LV mass index was consistently associated with 13% to 61% higher hazard for 
cardiovascular events (all P<0.01), independent of age, sex, body mass index, valvuloarterial impedance, LV ejection 
fraction and concentricity, and the presence of concomitant hypertension.
Conclusions—Higher LV mass index is independently associated with increased cardiovascular morbidity and mortality 
during progression of aortic stenosis.
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hypothesis that higher LV mass is independently associated 
with higher rate of cardiovascular events in these patients.
Methods
Patient Population
The present analysis was prespecified within the Simvastatin 
Ezetimibe in Aortic Stenosis (SEAS) study analysis plan. Study de-
sign, baseline characteristics, and main outcome results of the SEAS 
study have previously been published.12,13 In short, 1873 men and 
women aged 45 to 85 years with asymptomatic mild-to-moderate AS 
having a peak aortic jet velocity between 2.5 and 4.0 m/s by echo-
cardiography were randomized to placebo or to combination treat-
ment with simvastatin 40 mg and ezetimibe 10 mg daily. Patients with 
known coronary heart disease, heart failure, diabetes mellitus, history 
of stroke or peripheral vascular disease, clinically significant mitral 
valve disease, severe or predominant aortic regurgitation, rheumatic 
valvular disease, aortic valve prosthesis, or renal insufficiency and 
patients already on lipid-lowering therapy or with a guideline indica-
tion for lipid-lowering therapy were not included in the SEAS study. 
Core laboratory readings of peak aortic jet velocity and LV mass 
were available from baseline and at least 1 follow-up echocardio-
gram in 1656 patients (88% of the study population), who comprise 
the present study population. Hypertension was defined as history 
of hypertension, use of antihypertensive drug treatment, or elevated 
blood pressure at the baseline clinic visits. All patients gave written 
informed consent, and the study was approved by ethics committees 
in all participating countries.
Echocardiography
Echocardiograms were performed at baseline, annually and before 
planned aortic valve surgery following a standardized protocol at 
173 study centers in 7 European countries. Echocardiographic im-
ages were stored on videotapes, compact discs, or magnetic optical 
discs and forwarded for blinded interpretation at the SEAS echocar-
diography core laboratory at Haukeland University Hospital, Bergen, 
Norway, as previously published.5,12,14 Severity of AS and LV struc-
ture and function were measured following current guidelines.15,16 LV 
mass was measured by an autopsy-validated method and indexed to 
body height in the allometric power of 2.7.17 LV hypertrophy was 
defined using the prognostically validated cutoff values LV mass in-
dex >46.7 g/m2.7 in women and >49.2 g/m2.7 in men.3 Relative wall 
thickness was assessed from 2×LV posterior wall thickness/LV end-
diastolic diameter ratio and considered increased if >0.43 (concentric 
LV geometry).15 Valvuloarterial impedance was calculated using a 
previously validated method.18 Pressure recovery was assessed at the 
aortic sinotubular junction and used for calculation of energy loss 
index as prognostically validated.19,20
End Points
The prespecified primary end point of SEAS was major cardiovas-
cular events, a composite end point, including aortic valve–related 
events (combined aortic valve replacement, hospitalization for heart 
failure because of aortic stenosis, and death from cardiovascular 
causes) and ischemic cardiovascular events (combined death from 
cardiovascular causes, nonfatal myocardial infarction, hospitalization 
for unstable angina, coronary revascularization, and nonhemorrhagic 
stroke).12 The secondary end points were aortic valve events and isch-
emic cardiovascular events analyzed separately. Total mortality was 
a tertiary end point. All end points were classified by an independent 
end point classification committee whose members were unaware 
of study group assignments.13 We also assessed the post hoc defined 
composite end point of total mortality and hospitalization for heart 
failure because of aortic stenosis.
Statistical Analysis
Statistical analysis was performed using IBM SPSS version 22.0 
(IBM Corporation, Armonk, NY). Values are given as mean+SD 
for continuous variables and as percentages for categorical vari-
ables. Comparison between groups was performed by paired and 
unpaired t test, χ2 test, and general linear model with post hoc test 
and Bonferroni adjustment as appropriate. Cumulative incidences of 
cardiovascular events during follow-up were estimated by Kaplan–
Meier. Kaplan–Meier plots were used to compare event-free survival 
in groups of patients with and without LV hypertrophy at baseline. 
Correlates of the prespecified primary and secondary composite end 
points were identified by Cox regression analysis in univariable and 
multivariable models and presented as hazard ratio and 95% confi-
dence intervals. In the primary analyses, LV mass index was used as 
the continuous variable. In secondary models, LV hypertrophy as a 
dichotomous variable was used. Age, sex, body mass index, peak aor-
tic jet velocity, LV ejection fraction, concentric LV geometry, hyper-
tension, and valvuloarterial impedance were included as covariates in 
all multivariable models. Aortic valve replacement was included as a 
time-varying covariate in models assessing cardiovascular death and 
total mortality. In subsequent models, concentric LV geometry was 
replaced by stress-corrected midwall shortening, and the presence of 
aortic regurgitation was added. To take the progressive increase in 
LV mass during progression of AS into account, time-varying Cox 
regression analysis was used. Two-tailed P<0.05 was regarded as sta-
tistically significant both in univariable and multivariable analyses.
Results
Compared with patients with normal LV mass index at base-
line, the group with LV hypertrophy was older, had higher 
body mass index, lower LV midwall function, and included 
more patients with hypertension (all P<0.01; Tables 1 and 
2). During a median of 4.3-year follow-up, LV mass indexed 
to height2.7 (LV mass index) and concentricity increased, 
whereas LV endocardial and myocardial function declined 
(all P<0.001). The prevalence of LV hypertrophy increased 
from 36% at baseline to 60% at the last study visit (P<0.01). 
The annual AS progression rate did not differ between groups 
of patients with and without LV hypertrophy at baseline, 
whether calculated based on change in peak aortic jet velocity 
(0.21±0.39 versus 0.20±0.27 m/s per year), mean gradient (4±7 
versus 4±5 mm Hg/y), or aortic valve area (−0.03±0.25 versus 
−0.03±0.29 cm2/y, all P>0.3). The average time between the 
baseline and the last follow-up study was 3.6±1.2 years. The 
average time between the follow-up study and an aortic valve 
event, an ischemic cardiovascular event, and death from any 
cause was on average 0.59±0.03, 0.94±0.06, and 0.80±0.55 
years, respectively.
During follow-up, each SD higher unindexed LV mass, 
LV mass/height2.7, and LV mass/body surface area was asso-
ciated with comparable 21%, 23%, and 25% higher rates 
of the primary study end point, respectively, in univariable 
analyses (all P<0.001). The rates of aortic valve events, 
ischemic cardiovascular events, cardiovascular death, and 
combined death from any cause and hospitalization for heart 
failure because of progression of AS all increased progres-
sively with increasing quartile of baseline LV mass index 
and were 1.5, 1.8, 3.2, and 2.5 times higher in the upper LV 
mass index quartile than in the lowest quartile (Figure 1). 
In multivariable Cox regression, higher LV mass index was 
associated with higher rates of aortic valve events, ischemic 
cardiovascular events, cardiovascular death, and combined 
death from any cause and hospitalization for heart failure 
when adjusted for known prognosticators in AS patients like 
age, sex, body mass index, AS severity, LV ejection fraction, 
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concentric LV geometry, and concomitant hypertension 
(Table 3). Similar results were found in a second model, 
replacing concentric geometry by stress-corrected midwall 
shortening (hazard ratio, 1.13 for primary end point per 1 SD 
higher LV mass index [95% confidence interval, 1.02–1.24]; 
P=0.017). Adding the presence of aortic regurgitation or 
type of antihypertensive drug among the covariates did not 
influence results.
Table 1. Clinical Patient Characteristics in the Total Population and in Patients 
With or Without LV Hypertrophy at Baseline
Variable
Total Population, 
n=1616
LV Hypertrophy, 
n=592
No LV Hypertrophy, 
n=1064
Age, y 67.4±9.6 68.2±9.2* 66.9±9.8
Women, % 39.4 38.3 40.0
Systolic blood pressure, mm Hg 146±20 149±20* 145±20
Diastolic blood pressure, mm Hg 82±10 83±10† 81±10
Heart rate, bpm 66±11 66±11 66±12
Body surface area, m2 1.89±0.20 1.92±0.20* 1.88±0.20
Body mass index, kg/m2 26.8±4.3 28.5±4.6* 25.9±3.9
Baseline hypertension, % 83.0 88.2* 80.2
Baseline current smoker, % 19.0 15.4* 21.1
Serum creatinine, mg/dL 1.06±0.18 1.06±0.18 1.06±0.17
LV indicates left ventricular.
*P<0.01 vs no LV hypertrophy group.
†P<0.05 vs no LV hypertrophy group.
Table 2. Echocardiographic Findings in the Total Study Population and in 
Patients With or Without LV Hypertrophy at Baseline
Variable
Total Population, 
n=1616
LV Hypertrophy, 
n=592
No LV Hypertrophy, 
n=1064
LV end-diastolic diameter, cm 5.03±0.63 5.29±0.63* 4.89±0.57
LV end-systolic diameter, cm 3.19±0.55 3.42±0.57* 3.06±0.50
Interventricular septal thickness, cm 1.15±0.28 1.34±0.27* 1.05±0.22
Posterior wall thickness, cm 0.89±0.19 1.02±0.18* 0.81±0.14
LV fractional shortening, % 37±6 35±6* 37±6
LV ejection fraction, % 66±7 66±7* 67±6
Circumferential end-systolic stress, 
dyne/cm2
112±32 111±32 113±31
Midwall fractional shortening, % 17.0±3.3 15.6±3.0* 17.9±3.2
Stress-corrected midwall shortening, 
%
98±19 89±18* 102±19
Relative wall thickness 0.36±0.09 0.39±0.10* 0.34±0.08
LV mass, g 193±67 252±66* 160±39
LV mass index, g/m2.7 45.6±14.5 60.5±12.2* 37.3±7.1
Aortic valve velocity, m/s 3.08±0.54 3.18±0.56* 3.03±0.52
Aortic valve mean gradient, mm Hg 23±9 24±9* 22±8
Aortic valve area/body surface area, 
cm2/m2
0.67±0.23 0.66±0.22 0.68±0.24
Energy loss index, cm2/m2 0.90±0.46 0.86±0.43† 0.92±0.47
Stroke volume, mL 45±13 46±14† 44±13
Aortic regurgitation, % 60.2 62.2* 59.1
  Grade 1, % 43.4 41.6 44.3
  Grade 2, % 16.1 19.7 14.2
  Grade 3, % 0.7 0.9 0.6
LV indicates left ventricular.
*P<0.01 vs no LV hypertrophy group.
†P<0.05 vs no LV hypertrophy group.
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In a secondary set of models, having LV hypertrophy on 
the baseline echocardiogram was associated with higher rates 
of the primary and secondary composite study end points and 
combined all-cause death and hospitalization for heart failure, 
consistent with the outcome association demonstrated for LV 
mass index (Table 4; Figure 2).
In multivariable linear regression higher LV mass/
height2.7 at the last study echocardiogram was associated 
with male sex (β=0.06), and higher mean aortic gradient 
(β=0.15), systolic blood pressure (β=0.04), body mass index 
(β=0.14), initial LV mass/height2.7 (β=0.54), and presence of 
normal midwall shortening (β=0.05, all P<0.05) at the base-
line echocardiogram. To take into account the progressive 
increase in LV mass during progression of AS, a set of time-
varying Cox regression models were used. Higher LV mass 
index during follow-up was associated with a 16% higher 
rate of the primary study end point, 13% higher rate of aor-
tic valve events, 25% higher rate of ischemic cardiovascu-
lar events, 63% higher cardiovascular mortality, and 44% 
higher combined death from any cause and hospitalization 
Figure 1. Cumulative incidences of aortic valve events (AVE), ischemic cardiovascular (CV) events (ICE), CV death (CVD), and combined 
death from any cause and hospitalization for heart failure because of progression of aortic stenosis (DEATH&CHF) during >4.3 years of 
follow-up in relation to quartile of baseline left ventricular (LV) mass index in mild-to-moderate asymptomatic aortic stenosis.
Table 3. Impact of Baseline Left Ventricular Mass Index (Per 1 SD [15 g/m2.7] Higher) on the Rates of the Primary and 
Secondary Study End Points, Hospitalization for Heart Failure, Cardiovascular Death, All-Cause Death, and Combined All-
Cause Death and Hospitalization for Heart Failure During >4.3 Years of Follow-Up in Patients With Initially Asymptomatic 
AS
Study End Point No. of Events Unadjusted HR (95% CI) P Value Adjusted HR (95% CI)* P Value
Primary study end point 498 1.23 (1.14–1.37) <0.001 1.12 (1.02–1.23) 0.020
Aortic valve events 468 1.19 (1.11–1.29) <0.001 1.09 (0.99–1.19) 0.083
Aortic valve replacement 411 1.17 (1.07–1.27) <0.001 1.03 (0.93–1.14) 0.562
Heart failure due to progression of AS 36 1.47 (1.16–1.61) 0.001 na
Cardiovascular death 66 1.34 (1.12–1.70) <0.001 1.34 (1.07–1.67) 0.011
Ischemic cardiovascular events 232 1.28 (1.15–1.43) <0.001 1.28 (1.13–1.47) <0.001
Total mortality 129 1.27 (1.11–1.46) <0.001 1.19 (1.01–1.42) 0.048
Total mortality and hospitalization for 
heart failure
149 1.30 (1.15–1.47) <0.001 1.23 (1.05–1.44) 0.011
Univariable and multivariable Cox regression analyses. AS indicates aortic stenosis; CI, confidence interval; HR, hazard ratio; and na, multivariable 
analysis not performed because of low number of events.
*Adjusted for aortic jet velocity, sex, age, left ventricular ejection fraction, body mass index, randomized study treatment, hypertension, concentric left 
ventricular geometry, and valvuloarterial impedance.
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for heart failure (all P<0.01; Table 5). In subsequent mod-
els replacing energy loss index by peak aortic jet velocity, 
mean aortic valve gradient, or aortic valve area as measure 
of AS severity, or LV ejection fraction by midwall shorten-
ing or stress-corrected midwall shortening, the results did 
not change (data not shown).
Discussion
This is the first large prospective study to assess the prognostic 
impact of LV mass and hypertrophy assessed by echocardiog-
raphy in patients with asymptomatic mild-to-moderate AS 
without known coronary heart disease or diabetes mellitus. 
As demonstrated by our results, higher LV mass at baseline 
or during follow-up was associated with higher rates of both 
the primary and secondary prespecified composite study end 
points in the SEAS study, resulting in a considerably increased 
overall cardiovascular morbidity and mortality. These find-
ings were also independent of documented prognosticators 
in asymptomatic AS, including AS severity, hypertension, 
body mass index, sex, LV ejection fraction, and concentric LV 
geometry.4,7,8,21–23 Of note, patients in the highest versus lowest 
quartile of LV mass index at baseline had a 13% higher 4.3-
year cumulative incidence of aortic valve events and a 11% 
higher incidence of combined death from any cause and hos-
pitalization for heart failure, corresponding to absolute differ-
ences of 3.0% and 2.6% per year, respectively.
Traditionally, development of LV hypertrophy in AS has 
been considered a physiological, compensatory process taking 
advantage of Laplace’s law to sustain normal systolic func-
tion during chronically elevated systolic stress.4,24 However, 
as recently demonstrated, concomitant hypertension, obesity, 
and the presence of the metabolic syndrome have been associ-
ated with increased LV mass in patients with asymptomatic 
nonsevere AS, suggesting that development of LV hypertro-
phy is multifactorial also in patients with AS.5–7 The relatively 
larger impact of hypertension on LV wall volume in mild-to-
moderate AS than of AS itself has also been demonstrated in 
experimental simulation models by Garcia et al.25 However, 
having increased LV mass on the baseline echocardiogram 
was associated with increased event rates in the present study 
independent of the prognostic impact of concomitant hyper-
tension and increased body mass index previously demon-
strated in asymptomatic mild-to-moderate AS.21–23
Risk prediction in asymptomatic AS remains a chal-
lenge, including identification of AS patient with high risk 
for development of congestive heart failure, the most prog-
nostically severe complication of AS.26 Both American and 
European guidelines recommend aortic valve replacement in 
patients with severe AS irrespective of symptoms if LV dys-
function defined as LV ejection fraction <50% is present.27,28 
Population-based studies have demonstrated that increased LV 
mass was associated with incident heart failure independent of 
LV ejection fraction and independent of incident myocardial 
infarction.29–31 The present findings expands this knowledge 
by demonstrating that also in patients with mild-to-moderate 
AS, increased LV mass index is associated with higher rate of 
combined death and heart failure independent of LV systolic 
function. Current European guidelines suggest excessive LV 
hypertrophy unless because of hypertension among indica-
tions for aortic valve replacement in AS,28 as this has been 
associated with increased perioperative morbidity and mortal-
ity and may be less reversible after delayed surgery, precluding 
an optimal long-term prognosis.8,32 The present results from 
the large SEAS study document the association of increased 
LV mass with increased cardiovascular morbidity and mortal-
ity also in patients with asymptomatic mild-to-moderate AS 
independent of the presence of concomitant hypertension. Our 
findings contrast with previous reports from smaller studies in 
patients with moderate to-severe AS. Stewart et al33 following 
183 patients with initially asymptomatic moderate or severe 
AS for a median of 31 months found that neither LV mass nor 
tissue Doppler measures of LV systolic and diastolic function 
predicted outcome independent of AS severity. Similar find-
ings were reported by Monin et al34 in a study of 107 patients 
Table 4. Impact of Baseline Left Ventricular Hypertrophy on the Rates of the Primary and Secondary Study End 
Points, Hospitalization for Heart Failure, Cardiovascular Death, All-Cause Death, and Combined All-Cause Death and 
Hospitalization for Heart Failure During >4.3 Years of Follow-Up in Patients With Initial Asymptomatic AS
Study End Point No. of Events Unadjusted HR (95% CI) P Value Adjusted HR (95% CI)* P Value
Primary study end point 498 1.53 (1.30–1.81) <0.001 1.26 (1.03–1.54) 0.022
Aortic valve events 468 1.50 (1.27–1.79) <0.001 1.25 (1.02–1.54) 0.035
Aortic valve replacement 411 1.46 (1.22–1.76) <0.001 1.21 (0.97–1.52) 0.087
Heart failure due to progression of AS 36 2.08 (1.08–4.00) 0.028 na …
Cardiovascular death 66 1.68 (1.06–2.65) 0.026 1.35 (0.79–2.11) 0.277
Ischemic cardiovascular events 232 1.55 (1.22–1.98) <0.001 1.42 (1.06–1.89) 0.017
Total mortality 129 1.61 (1.17–2.23) 0.004 1.31 (0.89–1.94) 0.178
Total mortality and hospitalization for heart 
failure
149 1.67 (1.24–2.26) 0.001 1.35 (0.94–1.92) 0.110
Univariable and multivariable Cox regression analyses. AS indicates aortic stenosis; CI, confidence interval; HR, hazard ratio; and na, multivariable 
analysis not performed due to low number of events.
*Adjusted for aortic jet velocity, sex, age, left ventricular ejection fraction, body mass index, randomized study treatment, relative wall thickness, 
hypertension, and valvuloarterial impedance.
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with moderate-to-severe AS, who therefore did not include 
LV mass in the suggested risk assessment score for asymp-
tomatic patients with moderate-to-severe AS based on their 
findings. Electrocardiographic LV strain pattern was recently 
suggested as a strong correlate of mortality and hospitaliza-
tion for heart failure by Greve et al35 in a SEAS substudy. Of 
note, electrocardiographic strain pattern was not significantly 
associated with either cardiovascular death or all-cause mor-
tality when mean aortic gradient was included as covariate 
in their multivariable models, in contrast to the strong inde-
pendent association with echocardiographic LV mass and 
hypertrophy reported in the present article. However, Shah et 
al36 documented that electrocardiographic strain pattern as a 
highly specific marker of midwall myocardial fibrosis, reflect-
ing more advanced myocardial injury, LV decompensation, 
and impaired prognosis.35–37
Both LV mass and concentricity increased considerably 
during follow-up. Concentric LV geometric patterns have 
been demonstrated to carry individual risk of cardiovascular 
morbidity and mortality in hypertension.38 Furthermore, an 
association with reduced coronary flow reserve as a substrate 
for reduced myocardial function in hypertensive subjects with 
LV concentric geometry free from coronary artery disease has 
been reported by Galderisi et al.39 In patients operated for AS, 
both concentric LV geometry and excessive LV hypertrophy 
have been associated with higher postoperative mortality.8,9 
Cioffi et al10 previously demonstrated that excessive LV hyper-
trophy was the strongest correlate of combined death, conges-
tive heart failure, and nonfatal myocardial infarction in 218 
patients with asymptomatic severe AS. Of note, these findings 
were independent of patient age, extent of aortic valve cal-
cification, renal dysfunction, or the presence of concomitant 
diabetes mellitus, all factors that have been associated with 
worsened prognosis in previous studies in asymptomatic 
severe AS.10,40,41 The present results expand this knowledge 
by demonstrating the independent prognostic importance of 
higher LV mass in a large prospective study of patients with 
initially asymptomatic mild-to-moderate AS.
Figure 2. Survival free from major cardiovascular (CV) events (A), aortic valve events (B), ischemic CV events (C), and combined death 
from any cause and hospitalization for heart failure because of progression of aortic stenosis (AS; D) in groups of patients with (—) and 
without (—-) left ventricular hypertrophy (LVH) on the baseline echocardiogram.
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Limitations
Patients with known coronary heart disease, heart failure, dia-
betes mellitus, history of stroke or peripheral vascular disease, 
other clinically significant valve disease, rheumatic valve 
disease, or renal insufficiency and patients with a guideline 
indication for lipid-lowering therapy were not included in the 
SEAS study. Thus, projection of study results to these patient 
groups should be done with caution.
In the SEAS study, referral for aortic valve replacement 
was left to the decision of the attending cardiologist at the 173 
participating centers, and the basis for referral of individual 
patients for surgery was not captured in the study database. 
We cannot exclude that presence of extreme LV hypertrophy 
may have influenced the decision to refer for surgery in indi-
vidual cases. However, an independent impact of higher LV 
mass index was also found with the more objective end points 
cardiovascular and total mortality.
Several studies have found speckle strain imaging, in par-
ticular 2-dimensional (2D) global longitudinal strain, useful 
for detecting asymptomatic AS patients with more advanced 
LV injury despite normal LV ejection fraction.41–43 Lower 
global longitudinal strain in these patients has been associ-
ated with higher LV mass, concentric LV geometry, more 
severe AS, concomitant hypertension,41 and with impaired 
prognosis.42 Recently, Nagata et al43 reported the superior per-
formance of 3D compared with 2D global longitudinal strain 
for risk prediction in such patients, also when adjusting for 
LV mass in multivariate analysis. However, speckle tracking 
echocardiography was not included in the large SEAS study, 
where the majority of echocardiogram were recorded on video 
tapes during the period 2002 to 2008.
Maréchaux et al44 have demonstrated the usefulness of 
exercise stress echocardiography for risk stratification in 
asymptomatic patients with severe AS, and current European 
guidelines include exercise testing for additional risk assess-
ment in patients with asymptomatic severe AS.28 However, 
exercise testing was not included in the large SEAS study, 
which was undertaken in 173 study centers during the years 
2002 to 2008.
Conclusions
In patients with asymptomatic AS, higher LV mass index is 
independently associated with increased cardiovascular mor-
bidity and mortality during progression of valve stenosis.
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CLINICAL PERSPECtIVE
It is well known that the presence of left ventricular (LV) hypertrophy by echocardiography predicts increased cardiovas-
cular morbidity and mortality both in general and hypertensive populations. In patients with aortic valve stenosis (AS), LV 
hypertrophy has traditionally been considered as an adaptive response that keeps LV wall stress close to normal, offsetting 
the hemodynamic load. Recent publications have demonstrated that the presence of concomitant hypertension, obesity, and 
metabolic syndrome significantly modulates LV mass and geometry in patients with asymptomatic AS independent of AS 
severity. Furthermore, excessive LV hypertrophy in severe AS has been associated with incident heart failure and increased 
mortality. The present study is the first to demonstrate the prognostic impact of LV mass and hypertrophy in a large, pro-
spective study in asymptomatic mild-to-moderate AS. Higher LV mass at baseline or during follow-up was associated with 
considerable increased overall cardiovascular morbidity and mortality. The findings were independent of other documented 
prognosticators in asymptomatic AS. Patients in the highest versus the lowest quartile of baseline LV mass index had 2.6% 
higher incidence per year of death and hospitalization for heart failure. Emerging data suggest that speckle strain echocar-
diography may be used for further identification of AS patients with more advanced LV injury. Whether asymptomatic AS 
patients with LV hypertrophy should undergo valve replacement at an earlier stage of disease remains unknown. However, 
LV hypertrophy in asymptomatic AS should not be regarded as purely compensatory, and referral to a heart valve center for 
further evaluation may be indicated.
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